|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TARBP1 |
Gene summary for TARBP1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TARBP1 | Gene ID | 6894 |
| Gene name | TAR (HIV-1) RNA binding protein 1 | |
| Gene Alias | TRM3 | |
| Cytomap | 1q42.2 | |
| Gene Type | protein-coding | GO ID | GO:0001510 | UniProtAcc | Q13395 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 6894 | TARBP1 | CCI_2 | Human | Cervix | CC | 2.16e-02 | 4.93e-01 | 0.5249 |
| 6894 | TARBP1 | CCI_3 | Human | Cervix | CC | 1.36e-11 | 7.62e-01 | 0.516 |
| 6894 | TARBP1 | sample3 | Human | Cervix | CC | 2.04e-02 | 8.57e-02 | 0.1387 |
| 6894 | TARBP1 | HTA11_3410_2000001011 | Human | Colorectum | AD | 6.11e-09 | -4.12e-01 | 0.0155 |
| 6894 | TARBP1 | HTA11_2487_2000001011 | Human | Colorectum | SER | 1.06e-07 | -5.48e-01 | -0.1808 |
| 6894 | TARBP1 | HTA11_696_2000001011 | Human | Colorectum | AD | 5.96e-06 | -4.31e-01 | -0.1464 |
| 6894 | TARBP1 | HTA11_866_2000001011 | Human | Colorectum | AD | 5.58e-06 | -3.74e-01 | -0.1001 |
| 6894 | TARBP1 | HTA11_5212_2000001011 | Human | Colorectum | AD | 3.81e-03 | -6.55e-01 | -0.2061 |
| 6894 | TARBP1 | HTA11_866_3004761011 | Human | Colorectum | AD | 1.39e-02 | -3.99e-01 | 0.096 |
| 6894 | TARBP1 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 8.90e-03 | -2.95e-01 | 0.3005 |
| 6894 | TARBP1 | F007 | Human | Colorectum | FAP | 1.27e-03 | -4.00e-01 | 0.1176 |
| 6894 | TARBP1 | A001-C-207 | Human | Colorectum | FAP | 7.13e-04 | -3.70e-01 | 0.1278 |
| 6894 | TARBP1 | A015-C-203 | Human | Colorectum | FAP | 4.90e-28 | -4.62e-01 | -0.1294 |
| 6894 | TARBP1 | A015-C-204 | Human | Colorectum | FAP | 1.41e-05 | -3.64e-01 | -0.0228 |
| 6894 | TARBP1 | A002-C-201 | Human | Colorectum | FAP | 1.27e-11 | -4.17e-01 | 0.0324 |
| 6894 | TARBP1 | A001-C-119 | Human | Colorectum | FAP | 5.12e-04 | -3.92e-01 | -0.1557 |
| 6894 | TARBP1 | A001-C-108 | Human | Colorectum | FAP | 2.10e-14 | -2.74e-01 | -0.0272 |
| 6894 | TARBP1 | A002-C-205 | Human | Colorectum | FAP | 2.00e-18 | -3.93e-01 | -0.1236 |
| 6894 | TARBP1 | A001-C-104 | Human | Colorectum | FAP | 2.84e-04 | -1.87e-01 | 0.0184 |
| 6894 | TARBP1 | A015-C-006 | Human | Colorectum | FAP | 2.90e-09 | -1.70e-01 | -0.0994 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:003447015 | Esophagus | ESCC | ncRNA processing | 300/8552 | 395/18723 | 3.09e-35 | 3.26e-32 | 300 |
| GO:003466012 | Esophagus | ESCC | ncRNA metabolic process | 346/8552 | 485/18723 | 4.35e-31 | 2.51e-28 | 346 |
| GO:00434143 | Esophagus | ESCC | macromolecule methylation | 199/8552 | 316/18723 | 3.44e-10 | 9.57e-09 | 199 |
| GO:00080333 | Esophagus | ESCC | tRNA processing | 92/8552 | 127/18723 | 7.83e-10 | 1.93e-08 | 92 |
| GO:00063992 | Esophagus | ESCC | tRNA metabolic process | 122/8552 | 179/18723 | 9.03e-10 | 2.19e-08 | 122 |
| GO:00322592 | Esophagus | ESCC | methylation | 222/8552 | 364/18723 | 2.26e-09 | 5.09e-08 | 222 |
| GO:00094512 | Esophagus | ESCC | RNA modification | 114/8552 | 167/18723 | 2.76e-09 | 6.04e-08 | 114 |
| GO:00015101 | Esophagus | ESCC | RNA methylation | 58/8552 | 83/18723 | 6.87e-06 | 6.94e-05 | 58 |
| GO:00064002 | Esophagus | ESCC | tRNA modification | 62/8552 | 90/18723 | 7.02e-06 | 7.04e-05 | 62 |
| GO:00304881 | Esophagus | ESCC | tRNA methylation | 30/8552 | 41/18723 | 3.27e-04 | 1.93e-03 | 30 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TARBP1 | SNV | Missense_Mutation | novel | c.967N>C | p.Asp323His | p.D323H | Q13395 | protein_coding | deleterious(0.01) | possibly_damaging(0.598) | TCGA-A7-A4SD-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
| TARBP1 | SNV | Missense_Mutation | novel | c.1716G>T | p.Trp572Cys | p.W572C | Q13395 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-A7-A56D-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
| TARBP1 | SNV | Missense_Mutation | c.3445N>A | p.Asp1149Asn | p.D1149N | Q13395 | protein_coding | deleterious(0.01) | possibly_damaging(0.82) | TCGA-A8-A093-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| TARBP1 | SNV | Missense_Mutation | rs778242645 | c.1310G>C | p.Gly437Ala | p.G437A | Q13395 | protein_coding | deleterious(0) | possibly_damaging(0.656) | TCGA-A8-A0A2-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
| TARBP1 | SNV | Missense_Mutation | rs754357411 | c.4406N>T | p.Ser1469Leu | p.S1469L | Q13395 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AC-A5XS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
| TARBP1 | SNV | Missense_Mutation | rs778242645 | c.1310N>C | p.Gly437Ala | p.G437A | Q13395 | protein_coding | deleterious(0) | possibly_damaging(0.656) | TCGA-AR-A1AY-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unspecific | Doxorubicin | SD |
| TARBP1 | SNV | Missense_Mutation | c.2942N>C | p.Ser981Thr | p.S981T | Q13395 | protein_coding | tolerated(0.06) | possibly_damaging(0.836) | TCGA-B6-A0RG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| TARBP1 | SNV | Missense_Mutation | c.3473G>A | p.Arg1158His | p.R1158H | Q13395 | protein_coding | tolerated(0.07) | benign(0.209) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TARBP1 | SNV | Missense_Mutation | novel | c.4018C>G | p.Gln1340Glu | p.Q1340E | Q13395 | protein_coding | deleterious(0) | probably_damaging(0.926) | TCGA-C8-A3M7-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
| TARBP1 | SNV | Missense_Mutation | rs778242645 | c.1310G>C | p.Gly437Ala | p.G437A | Q13395 | protein_coding | deleterious(0) | possibly_damaging(0.656) | TCGA-E9-A1RE-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |